11 / 24
mFOLFOX6 as 2
nd
-line therapy for MPC
(PANCREOX)
Gill et al, J Clin Oncol 2016
OS
PFS (primary endpoint)
6.1 m vs 9.9 m, HR 1.78, p 0.024, follow up 8.8 m
3.1 m vs 2.9 m, HR 1.0, p 0.98
-Patients
were stratified
according to age (<70 years, ≥70 years), sex, ECOG (0, 1, or 2), and presence
of liver metastases.